Axcess Instruments presents a compelling case for a single-use, UHD laparoscopic imaging system designed to eliminate surgical interruptions and reduce facility turnover times. The deck highlights significant pain points in current reusable systems, such as lens fogging and high reprocessing costs ($100 per procedure). With 13 utility patents and a working prototype, the company is seeking $2.2 million to fund FDA testing, application, and initial marketing. Their financial projections are aggressive, targeting a jump from $0 in Year 1 to $55.2 million in Net Revenue by Year 5, with EBITDA re…
Key takeaways
- The company is seeking $2.2 million in funding, with 32% allocated to FDA testing and application (Slide 11).
- Axcess Instruments claims to reduce surgical room turnover times by 10-20% by eliminating instrument reprocessing (Slide 3).
- The product features 4K imaging, AI-enabled visualization, and internal patented lens cleaning to prevent fogging (Slide 3).
- The total addressable market is cited as an $8.3 billion global laparoscopic market with a 7-8% annual growth rate (Slide 5).
- Financial projections estimate reaching $55.2 million in net revenue and $14.8 million in EBITDA by Year 5 (Slide 7).
- The company holds 13 utility patents and has a working contract with the Texas Heart Institute (Slide 8).
- The business model relies on direct and recurring sales, with revenue generation starting in Year 2 (Slide 4).
- The team includes a CEO with 30 years of surgery experience and a VP with a background in oilfield development exits (Slide 9).
Axcess Instruments: The Case for Disposable UHD Laparoscopy
Axcess Instruments enters a highly competitive medical device field with a clear value proposition: replacing expensive, high-maintenance reusable laparoscopic cameras with a high-definition, single-use alternative. The 14-slide deck focuses heavily on the operational efficiencies gained by hospitals and the technical superiority of their 4K, AI-enabled imaging system. With a $2.2 million ask, the company is positioning itself for a rapid transition from R&D to commercialization.
Slide 1: Title Slide
The deck opens with the Axcess Instruments logo and the tagline "Single Use Replacement for Laparoscopic Systems." It includes the company website and a background image of a surgical team, immediately establishing the sector. The branding is professional and minimalist, focusing on the core product utility.
Slide 2: Laparoscopic Challenges
This slide identifies three primary pain points: surgeon inefficiency, camera limitations, and surgical room turnover time. It notes that current procedures are frequently interrupted for camera cleaning and that limited resolution produces low-quality images. Crucially, it highlights that current instruments require extensive cleaning, which slows down the turnover of operating rooms.
Slide 3: Axcess Instruments Solutions
The solution slide is dense with features. It promises "Faster Procedure – No Interruptions" through an internal patented lens cleaning system and 4K images. Key technical claims include AI-enabled visualization and "natural camera steering" where left is left and right is right—a common ergonomic complaint among surgeons. It also mentions a $100 per procedure saving by eliminating reprocessing.
Slide 4: Business Model
Axcess describes a "Direct + Recurring Sales" model. They project revenue generation in Year 2 and becoming cashflow positive in Year 3. The slide mentions a "Plug + Play Model" targeting hospitals and ambulatory surgery centers. Interestingly, it teases a "future SaaS model," though it provides no details on how software-as-a-service would integrate with a hardware-heavy disposable device.
Slide 5: Market Opportunity
The market is visualized as a series of concentric circles. The global laparoscopic market is valued at $8.3 billion with a 7-8% annual growth rate. The US laparoscopic market is $2.8 billion, and the US trocar market is $700 million. The slide also lists specific procedure volumes: 1,000,000 US gallbladder surgeries and 500,000 US tubal ligations annually, providing a clear target for their initial market share.
Slide 6: Competition
A comparison matrix pits AxcessPort against Stryker, Olympus, and New View. Axcess claims superiority in AI camera technology, surgeon-friendly steering, and universal facility operations. While New View is credited with having an uninterrupted procedure and being single-use, Axcess claims to be the only one offering the full suite of AI and ergonomic features.
Slide 7: Financial Projections
The financial slide shows a steep growth curve. Net revenue is projected to grow from $3.3 million in Year 2 to $55.2 million in Year 5. Operating expenses remain relatively low, scaling from $1 million to $2.6 million over the same period. The projected EBITDA for Year 5 is $14,877,828, suggesting a highly scalable model if the COGS (projected at $37.6 million in Year 5) can be maintained.
Slide 8: Traction
This slide serves as the credibility anchor. It lists 13 utility patents, a working prototype manufactured by Synectic and Huck Medical, and a working contract with the Texas Heart Institute. It also includes a quote from a "Major Medical University" praising the single-package approach. The next steps are clearly defined: FDA application and approval.
Slide 9: Team
The leadership consists of Michael J. Norton, MD (CEO), who brings 30 years of surgical experience and 13 patents, and Noel Ischy (VP), who has a background in finance and oilfield development exits. While Dr. Norton provides the necessary clinical authority, the VP's background is less traditional for medtech, though his exit experience is noted.
Slide 10: Team Partners
To bolster the lean internal team, this slide lists external partners: Locke Lord for IP and M&A, Synectic for manufacturing, 40AU for software and firmware, and Huck Medical for device development. This demonstrates a decentralized but professional operational structure.
Slide 11: Financials (The Ask)
The company is seeking $2,200,000. The allocation is broken down into: $300k for FDA prototype, $700k for FDA testing/application, $400k for operations, $200k for materials, and $600k for marketing and sales in Year 2. The pie chart provides a visual representation of this 24-month runway.
Slide 12-14: Closing and Disclosure
The final slides reiterate the value proposition for surgeons, patients, and hospitals. Slide 13 provides contact information for the two principals, and Slide 14 contains a standard legal disclosure regarding forward-looking statements and the confidential nature of the presentation.
What Axcess Instruments Does Well
The deck is exceptionally strong at identifying a specific, high-cost friction point in the surgical workflow: the cleaning and reprocessing of reusable cameras. By attaching a specific dollar value ($100 per procedure) and a time metric (10-20% turnover increase) to the problem, they make a compelling economic case for hospital administrators. The technical features, particularly the "natural steering" and internal lens cleaning, address real-world surgeon frustrations, which is vital for adoption. Furthermore, the inclusion of 13 utility patents and a partnership with the Texas Heart Institute provides the necessary "moat" and validation required for a medtech investment.
What is Missing from the Deck
The most significant omission is a detailed regulatory timeline. While they allocate $700,000 for FDA testing, there is no mention of whether they are pursuing a 510(k) pathway or a more rigorous De Novo/PMA process. Given that they claim "AI-enabled visualization," the regulatory hurdle may be higher than a standard laparoscopic tool. Additionally, the "future SaaS model" mentioned on Slide 4 is entirely unsupported; there is no explanation of what data is being captured or who would pay for the software. Finally, the competitive landscape is limited to four names; a more thorough analysis of emerging single-use competitors in the endoscopy space would provide more context for their valuation.
Founder Takeaways: What to Copy
Quantify the Inefficiency: Axcess doesn't just say current systems are slow; they cite the $100 reprocessing cost and the specific percentage of room turnover improvement. Always turn qualitative pain into quantitative data. · Leverage Clinical Authority: Having a CEO who is an MD with 30 years of experience and the holder of the patents is a massive advantage. If your founder is the end-user of the product, highlight that experience prominently. · Clear Use of Funds: Slide 11 is a model for transparency. It breaks down the $2.2M ask into specific buckets that align with the company's stated milestones (FDA approval and Year 2 sales). · Strategic Partnerships: For lean startups, showing that you have outsourced specialized functions (like IP law and firmware development) to reputable firms builds confidence that the money won't be wasted on building unnecessary internal infrastructure.
Frequently asked questions
- What is the primary problem Axcess Instruments is solving?
- Axcess Instruments addresses inefficiencies in laparoscopic surgery, specifically procedure interruptions caused by camera cleaning and long surgical room turnover times. Current reusable systems require extensive cleaning and reprocessing, costing approximately $100 per procedure. Their single-use UHD system eliminates these steps, aiming to increase facility turnover by 10-20%.
- How does the technology differ from existing competitors like Stryker or Olympus?
- According to Slide 6, Axcess Instruments offers AI camera technology, 'natural' camera steering (left is left, right is right), and an irrigated cleaning system that competitors lack. Unlike major players Stryker and Olympus, Axcess provides a single-use disposable unit, which simplifies logistics and ensures a new, scratch-free lens for every surgery.
- What is the current stage of the product and regulatory path?
- The company has a working prototype manufactured by Synectic and Huck Medical. They currently hold 13 utility patents and a working contract with the Texas Heart Institute. The next critical milestones, funded by the requested $2.2 million, are the development of an FDA-ready prototype and the completion of the FDA application and approval process.
- What are the projected financials for Axcess Instruments?
- The deck projects $0 revenue in Year 1 during the FDA phase, followed by $3.3 million in Year 2. By Year 5, the company forecasts $55.2 million in net revenue with a cost of goods sold (COGS) of $37.6 million. They expect to become cashflow positive in Year 3 with an EBITDA of $6.1 million.
- Who are the key members of the leadership team?
- The team is led by Michael J. Norton, MD, FACS, who serves as CEO and brings 30 years of surgical experience and 13 patents. He is joined by Noel Ischy, VP of Oilfield Development, who has experience in finance and a previous exit in the oilfield drilling sector. They are supported by partners in IP law, product development, and software.
